10-Q: CytoSorbents Q2 2025: Revenue Up, Regulatory Hurdles Mount

CytoSorbents Corporation reports increased revenue and improved operating loss in Q2 2025, but faces significant regulatory setbacks for DrugSorb-ATR in the U.S. and Canada, raising going concern doubts.

Summary

• Total revenue for the six months ended June 30, 2025, was $18.3 million, an increase of 2.9% compared to $17.8 million in the prior year.
• Total revenue for the three months ended June 30, 2025, was $9.6 million, an increase of 8.8% compared to $8.8 million in the prior year.
• Gross profit for the six months ended June 30, 2025, decreased by 2.7% to $13.0 million from $13.4 million in the prior year, with gross margin declining to 71% from 75%.
• Loss from operations improved by 8.8% to $7.5 million for the six months ended June 30, 2025, compared to $8.2 million in the prior year, driven by a 5.0% reduction in total operating expenses.
• Net income attributable to common stockholders was $1.9 million for the three months ended June 30, 2025, and $0.5 million for the six months ended June 30, 2025, primarily due to significant foreign currency transaction gains.
• As of June 30, 2025, total cash, cash equivalents, and restricted cash amounted to $11.7 million, with $10.2 million being unrestricted and available for operations.
• The FDA issued a denial letter for the DrugSorb-ATR De Novo Request on April 25, 2025, citing remaining deficiencies.
• Health Canada issued a Notice of Refusal for the DrugSorb-ATR Medical Device License application on June 26, 2025, also identifying remaining deficiencies.
• A material weakness in internal control over financial reporting related to the accounting for non-cash stock-based compensation was identified and is actively being remediated.

Sentiment

Score: 3

Explanation: While revenue increased and operating loss improved, the significant regulatory setbacks for DrugSorb-ATR in both the U.S. and Canada, coupled with the explicit 'going concern' warning and declining gross margins, create substantial uncertainty and negative sentiment. The net income was primarily driven by non-operating foreign currency gains, not core business profitability.

Positives

• Total revenue increased by 2.9% to $18.3 million for the six months ended June 30, 2025, and by 8.8% to $9.6 million for the three months ended June 30, 2025.
• Loss from operations improved by 8.8% to $7.5 million for the six months ended June 30, 2025, due to a 5.0% reduction in total operating expenses.
• Reported net income of $1.9 million for the three months and $0.5 million for the six months ended June 30, 2025, largely driven by foreign currency transaction gains of $6.2 million and $9.2 million, respectively.
• Strengthened the balance sheet with $5.4 million net proceeds from a shareholder Rights Offering in January 2025 and an additional $1.4 million net proceeds from the exercise of Series A Right Warrants in February 2025.
• Received $1.7 million from the sale of 2023 and amended 2022 Net Operating Loss (NOL) and R&D tax credits.
• Research and development costs decreased by 22.4% to $2.9 million for the six months ended June 30, 2025, primarily due to the completion of the STAR-T clinical trial and other cost reductions.
• Selling, general and administrative expenses decreased by 1.3% for the six months ended June 30, 2025, partly due to the expiration of a 4% royalty in August 2024.
• Achieved Medical Device Single Audit Program (MDSAP) certification on November 1, 2024, for compliance with regulatory requirements in Canada, the United States, Brazil, Japan, and Australia.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern, with $11.7 million in total cash, cash equivalents, and restricted cash as of June 30, 2025.
• The FDA issued a denial letter for the DrugSorb-ATR De Novo Request on April 25, 2025, identifying remaining deficiencies that must be addressed.
• Health Canada issued a Notice of Refusal for the DrugSorb-ATR Medical Device License application on June 26, 2025, also identifying remaining deficiencies.
• Gross margin decreased to 71% for the six months ended June 30, 2025, from 75% in the prior year, primarily due to a $0.3 million inventory write-off and an 8.9% reduction in units produced.
• Interest expense, net, significantly increased to $1.2 million for the six months ended June 30, 2025, compared to $0.2 million in the prior year.
• The Series B Right Warrants, issued in connection with the Rights Offering, expired worthless on June 11, 2025, as the common stock's volume-weighted average price was below the minimum required exercise price of $2.00.
• A material weakness was identified in internal control over financial reporting related to the accounting for non-cash stock-based compensation, indicating a reasonable possibility of material misstatements.

Risks

• May not be successful in obtaining FDA or Health Canada authorization and successful commercialization for DrugSorb-ATR in the U.S. or Canada, respectively.
• Uncertainty of market acceptance for medical devices, including CytoSorb, ECOS-300CY, PuriFi pump, VetResQ, and product candidates such as DrugSorb-ATR, even with regulatory approvals.
• Future financial performance depends on the introduction and customer/healthcare community acceptance of products, which is influenced by regulatory clearance, demonstrated advantages, pricing, reimbursement policies, competition, and marketing effectiveness.
• Dependence on securing additional funding through equity offerings, debt financings, or other sources, with no assurance of obtaining funding on acceptable terms or at all, potentially leading to shareholder dilution.
• If additional capital is not available, the company may be required to slow sales and marketing expansion, delay further regulatory approvals, or reduce headcount.
• Future utilization of available net operating loss carryforward may be limited under Internal Revenue Code Section 382 due to changes in ownership.
• The identified material weakness in internal control over financial reporting could adversely affect the ability to record, process, summarize, and report financial information accurately.

Future Outlook

The company expects a final regulatory decision for DrugSorb-ATR in 2025 and anticipates rapid commercialization in the U.S. and Canada upon approval, targeting an initial addressable market of $300 million, growing to over $1 billion. Management believes DrugSorb-ATR has the potential to become an 'all-in-one countermeasure' for blood thinners. The company is pursuing appeal processes to resolve FDA and Health Canada deficiencies, with the FDA supervisory review expected to conclude by the end of August 2025. There is a potential to receive Tranche 2 of the Avenue Capital Commitment ($5 million) by December 31, 2025, and extend loan principal repayment terms to January 1, 2028, if revenue milestones are met.

Management Comments

• "We are making steady progress with this important initiative [German commercial team reorganization] and are pleased with this initial improvement in our second quarter of 2025, and remain confident it will lead to stronger execution and improved performance in Germany and our financial results overall this year."
• "We continue to believe that remaining deficiencies in its DeNovo application can be effectively resolved through this supervisory review process which is expected to be completed by the end of August 2025, and that a final regulatory decision can be achieved in 2025."
• "Upon approval, we expect to rapidly commercialize DrugSorb-ATR in the U.S. and Canada to address this large unmet medical need, with an initial estimated total addressable market of $300 million today to over $1 billion over time as we pursue additional indications for DrugSorb-ATR to remove additional classes of blood thinners and expansion of the antithrombotic removal application beyond cardiac surgery and across other surgical specialties. We believe that DrugSorb-ATR has the potential to become an all-in-one countermeasure for these agents."

Industry Context

The company operates in the blood purification and medical device sector, focusing on life-threatening conditions in intensive care and cardiac surgery. Its lead product, CytoSorb, is approved in the European Union and distributed in over 70 countries. DrugSorb-ATR is an investigational device aimed at antithrombotic removal in high-risk surgery, addressing a significant unmet medical need in the U.S. and Canada.

Management Changes

Corporate Governance

Legal Proceedings

• The company is, from time to time, subject to claims and litigation arising in the ordinary course of business.
• Currently, the company is not a party to any litigation or legal proceedings that, in management's opinion, are likely to have a material adverse effect on its business.

Related Party Transactions

• Approximately 1.4 million Series A Right Warrants were exercised by holders, including members of management and the Board of Directors, at an exercise price of $1.13 per warrant, providing an additional $1.6 million in aggregate gross proceeds ($1.4 million net of fees).

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and the risk of further stock price volatility due to regulatory uncertainties and the 'going concern' warning. The expiration of Series B warrants worthless indicates a negative impact on some warrant holders.
• Employees may face potential headcount reductions if additional capital is not secured, impacting job security.
• Customers in the EU and other markets will continue to have access to CytoSorb. Potential customers in the U.S. and Canada await regulatory approvals for DrugSorb-ATR, which could address a significant unmet medical need.
• Creditors, particularly Avenue Capital Group, have loan terms tied to regulatory approvals and revenue milestones, impacting the company's ability to extend repayment terms and draw additional tranches of funding.

Next Steps

• Resolve remaining deficiencies in the DrugSorb-ATR De Novo application through the FDA supervisory review process, expected to be completed by the end of August 2025.
• Achieve a final regulatory decision for DrugSorb-ATR in the U.S. in 2025.
• Pursue Health Canada's prescribed reconsideration process for the DrugSorb-ATR Medical Device License application, with a potential formal appeal if reconsideration is unsuccessful.
• Rapidly commercialize DrugSorb-ATR in the U.S. and Canada upon receiving regulatory approvals.
• Pursue additional indications for DrugSorb-ATR to remove other classes of blood thinners and expand its application beyond cardiac surgery.
• Draw Tranche 2 of the Avenue Capital Commitment ($5 million) between July 1, 2025, and December 31, 2025, contingent on FDA marketing approval of DrugSorb-ATR.
• Achieve the Interest-Only Milestone for the Avenue Capital Commitment (at least $25 million revenue for the trailing six months ended June 30, 2026) to extend the interest-only period.
• Continue implementing measures to strengthen internal control over financial reporting, including redesigning procedures and enhancing documentation related to stock-based compensation.
• Present a World Sepsis Day Global Webinar on September 10, 2025.

Key Dates

Recommendation

The company faces critical regulatory setbacks for its key pipeline product, DrugSorb-ATR, in major markets (U.S. and Canada), which casts significant doubt on its near-term growth prospects and ability to secure crucial Tranche 2 funding. The explicit 'going concern' warning, coupled with declining gross margins and reliance on non-operating foreign currency gains for net income, indicates fundamental operational challenges and high financial risk. While revenue saw a modest increase, the core profitability metrics are weak, and the failure of Series B warrants to be exercised due to low stock price reflects poor market sentiment. The need for further capital raises, with potential for dilution, adds to the negative outlook.

Keywords

CytoSorbents, CTSO, SEC filing, 10-Q, blood purification, medical devices, DrugSorb-ATR, FDA approval, Health Canada, regulatory denial, going concern, financial results, Q2 2025, revenue, gross profit, operating loss, capital raise, stock-based compensation, internal controls, corporate governance, ticagrelor, apixaban, rivaroxaban, cardiothoracic surgery, sepsis, critical care